CervoMed (CRVO) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary

Business and financial progress

• Completed all objectives post-reverse merger, including raising $50 million and securing analyst coverage.

• PIPE financing in March/April 2024 raised another $50 million, extending cash runway into late 2025.

• Step-up warrant could bring in up to $100 million if exercised by mid-2025, contingent on phase IIb results.

• Achieved strong business momentum and financial stability, supporting ongoing R&D.

Clinical development and scientific advances

• Completed enrollment for phase IIb trial in June 2024; last patient visit for primary endpoint in October, with top-line data expected in December.

• Three major scientific publications support phase IIa results and drug potential in DLB.

• Drug neflamapimod targets p38 alpha kinase, aligning with DLB pathophysiology and showing promising early-stage efficacy.

• Phase IIa data show positive results, especially in early-stage DLB patients, with strong biomarker and EEG support.

• Biomarkers like p-tau181 and GFAP used for patient selection and efficacy assessment.

Industry context and competitive landscape

• DLB now recognized as a disease of cholinergic deficit, with strong scientific consensus and support at major conferences.

• 14 of 22 Lewy body research centers participated in the phase IIb trial, including top UK centers.

• Limited controversy around the drug’s mechanism in DLB; enthusiasm driven by robust science and clinical data.

• Pharmaceutical industry focus on Alzheimer's and protein/antibody approaches has limited DLB drug development.